Health‐related quality of life in Waldenstrom Macroglobulinemia and IgM‐related disorders: A single institution experience

Frustaci, Anna Maria; Nichelatti, Michele; Deodato, Marina; Zamprogna, Giulia; Minga, Periana; Pioltelli, Maria Luisa; Cairoli, Roberto; Tedeschi, Alessandra

doi:10.1002/hon.2699

Cited by 5 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a wide variation in chemoimmunotherapies available (46 differing frontline regimens amongst 302 participants); therefore, it is difficult to compare this cohort with our data. An Italian single institute reported on PROMs in 143 patients with WM, monoclonal gammopathy of undetermined significance or an IgM‐associated disorder [ 15 ] using EORTC QLQ‐C30, HADS and EQ‐5D‐5L, as in our cohort, as well as FACT‐GOG neurotoxicity (Functional Assessment of Cancer Therapy‐Gynaecologic Oncology Group). Comparing treated, untreated and IgM‐associated disorders, no differences were found amongst most questionnaires (EORTC QLQ‐C30, HADS anxiety and depression scores or FACT‐GOG neurotoxicity score), although differences were seen in the EuroQoL‐5D visual analogue scale score with significantly worse scores in treated patients compared with untreated and IgM‐associated disorders.…”

Section: Resultsmentioning

confidence: 99%

Patient reported outcome measures in Waldenström macroglobulinaemia: A real‐world data analysis from the WMUK Rory Morrison Registry

Khwaja

Uppal

Bristogiannis

et al. 2022

eJHaem

View full text Add to dashboard Cite

Waldenström macroglobulinaemia (WM) is an incurable chronic B-cell malignancy, but highly responsive to treatment. Treatments include fixed-duration chemotherapy and continuous oral chemoimmunotherapy. In this expanding field, it is important to have reliable information on the impact of the various therapies on patients' quality of life (QoL). Patient reported outcome measures (PROMs) are increasingly recognised as important to understand patient experience of disease beyond traditional clinical outcome measures. Four QoL questionnaires (EORTC QLQ-C30 [European Organisation for Research and Treatment of Cancer quality of life core questionnaire], BIPQ [Brief Illness Perception Questionnaire], HADS [Hospital Anxiety and Depression Scale], EQ-5D-5L [EuroQoL 5-dimensional descriptive system questionnaire]) are embedded in the UK national WM registry, the Rory Morrison Registry. We reviewed the results from a snapshot of PROMs. As of November 2021, 155 patients completed PROM datawith 98% completion rate across all 58 questions. Complete clinical information was available for 52 patients. The majority of QoL questions (69%) failed to elicit a notable median response. Only four questions elicited statistically significant responses when comparing groups, and these were exclusively found in the EuroQoL-5D-5L and HADS questionnaires. Our data suggest that widely used questionnaires may not be suitable for patients with WM. We advocate the development of WM-specific outcome measures to overcome this.

show abstract

Section: Resultsmentioning

confidence: 99%

Patient reported outcome measures in Waldenström macroglobulinaemia: A real‐world data analysis from the WMUK Rory Morrison Registry

Khwaja

Uppal

Bristogiannis

et al. 2022

eJHaem

View full text Add to dashboard Cite

show abstract

“…EQ‐5D‐5L was the most commonly (8/17; 47%) employed questionnaire [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. FACT‐GOG assessed QOL burden when the disease was complicated by peripheral neuropathy.…”

Section: Figurementioning

confidence: 99%

“…Traditionally, the QoL of patients with WM has been related to age and comorbidities, [ 6 ] but the disease itself may adversely affect patients’ mental health. Indeed, newly diagnosed patients report post‐traumatic stress, which diminishes gradually provided no treatment is required [ 13 ].…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Systematic literature review of quality‐of‐life questionnaires in Waldenström macroglobulinaemia—need for a disease‐specific tool

Bristogiannis

Khwaja

Lwin

et al. 2023

eJHaem

View full text Add to dashboard Cite

“…The first in class BTK inhibitor, ibrutinib, is widely used in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma and Waldenström’s macroglobulinemia. Despite patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia might experience disease-related neuropathy [ 83 , 84 , 85 ], ibrutinib-induced neuropathy has also been reported. In a phase 2 study in relapsed-refractory patients, 13% developed any grade neuropathy but 0.5% was of grade 3 or 4.…”

Section: Novel Anticancer Drugs and Peripheral Neurotoxicitymentioning

confidence: 99%

Neurological Complications of Conventional and Novel Anticancer Treatments

Alberti

Salvalaggio

Argyriou

et al. 2022

Cancers

View full text Add to dashboard Cite

Various neurological complications, affecting both the central and peripheral nervous system, can frequently be experienced by cancer survivors after exposure to conventional chemotherapy, but also to modern immunotherapy. In this review, we provide an overview of the most well-known adverse events related to chemotherapy, with a focus on chemotherapy induced peripheral neurotoxicity, but we also address some emerging novel clinical entities related to cancer treatment, including chemotherapy-related cognitive impairment and immune-mediated adverse events. Unfortunately, efficacious curative or preventive treatment for all these neurological complications is still lacking. We provide a description of the possible mechanisms involved to drive future drug discovery in this field, both for symptomatic treatment and neuroprotection.

show abstract

Health‐related quality of life in Waldenstrom Macroglobulinemia and IgM‐related disorders: A single institution experience

Cited by 5 publications

References 11 publications

Patient reported outcome measures in Waldenström macroglobulinaemia: A real‐world data analysis from the WMUK Rory Morrison Registry

Patient reported outcome measures in Waldenström macroglobulinaemia: A real‐world data analysis from the WMUK Rory Morrison Registry

Systematic literature review of quality‐of‐life questionnaires in Waldenström macroglobulinaemia—need for a disease‐specific tool

Neurological Complications of Conventional and Novel Anticancer Treatments

Contact Info

Product

Resources

About